Gendel Limited

Gendel is a life science company which was spun out of the University of Ulster in December 1998 to develop a platform technology based on cell sensitisation followed by the application of low intensity ultrasound

The company is currently developing an application of this technology for the treatment of solid cancer tumours and has recently been granted the necessary approvals to commence human clinical trials.

Unlike most conventional cancer therapies, Gendel’s combined Electric Field and Ultrasound (CEFUS) therapy does not involve the use of drugs or surgical intervention and can be administered in minutes with minimal discomfort and no expected side effects. It has the potential to be used as either a stand-alone treatment or in conjunction with other therapies.

Enterprise Equity initially invested in March 2000 and together with other institutional, private and government investors, has continued to support the company up to this key stage of development.

Chief Executive Officer: Les Russell
Enterprise Equity Contact: Aidan Langan

<< BACK